Drugs developer Summit Therapeutics has put out so many updates this year, it is hard to know what else it could include that is new in Tuesday's results.
As a pre-revenue company, the figures will be largely irrelevant, though of course the cash burn will be of interest, as it is with all early stage biopharmaceuticals companies.
What investors will really want to see are signs of how quickly the company is progressing towards the “inflection point” chief executive officer Glyn Edwards was talking about last November.
The company has two main programmes on the go: one for the treatment of Duchenne muscular dystrophy (DMD), a fatal muscle wasting disease that mainly affects boys; and the other is an antibiotic to combat hospital superbug C.Diff.
News flow on both programmes has been nothing but positive this year.
Last month, the C.Diff candidate (ridinilazole) got a boost as the US patent and trademark office granted a "composition of matter" patent. It gives a period of exclusivity for in the United States until at least December 1, 2029, with the possibility of it being extended.
A few days before that announcement, the company revealed the US Food and Drug Administration had allowed the company to broaden the scope of its phase II clinical trial of its drug ezutromid to trial sites in the US.
Significant announcements expected
Trading statements: Coca-Cola HBC (LON:CCH)